


PHARMACEUTICAL 2022

RIGEL PHARMACEUTICALS INC Rank 113 of 475







PHARMACEUTICAL 2022

RIGEL PHARMACEUTICALS INC Rank 113 of 475



The relative strengths and weaknesses of RIGEL PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RIGEL PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 455% points. The greatest weakness of RIGEL PHARMACEUTICALS INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 312% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	154,467
Cost of Goods Sold	1,083
Intangible Assets	0
Liabilities, Current	63,554
Liabilities, Non-Current	0
Other Assets	10,677
Other Compr. Net Income	-98
Other Expenses	8,986
Other Liabilities	0
Other Net Income	47
Property and Equipment	2,184
Research and Development	65,237
Revenues	149,236
Selling, General and Administrative Expense	91,891

Output Variable	Value in 1000 USD
Assets	167,328
Liabilities	63,554
Expenses	167,197
Stockholders Equity	103,774
Net Income	-17,914
Comprehensive Net Income	-17,963
Economic Capital Ratio	36%